A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...

Its psoriasis drug risankizumab is under review with the FDA after strong phase 3 results and could be launched next year if things go well with the regulator. And AbbVie’s rheumatoid arthritis ...

Irritable bowel syndrome (IBS) can mimic some symptoms of inflammatory bowel disease (IBD). Learn how their causes, diagnosis ...

The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...

Welcome to the Crohn's Disease Clinical Case Review, a series of case presentations by clinicians in the field of Crohn's disease. In this video, Florence-Damilola Odufalu, MD, assistant professor ...